貨號：GS40368

Lecanemab is a humanized IgG1 monoclonal antibody that selectively targets and binds to soluble amyloid-beta (Aβ) protofibrils, which are transient, neurotoxic aggregates implicated in the progression of Alzheimer's disease. By binding to these soluble aggregates, lecanemab promotes their clearance from the brain, thereby reducing amyloid plaque burden. It is fully approved by the U.S. FDA and other regulatory agencies for the treatment of early Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology), based on clinical evidence demonstrating a significant slowing of cognitive and functional decline.